ArticleFrontiers in oncology2021

Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.

Tin-Yun Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.